Compare Anheuser-Busch Inbev SA (BUD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Johnson & Johnson — how do they compare? Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B), while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 3.9× Anheuser-Busch Inbev SA's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| BUD | JNJ | |
|---|---|---|
Market Cap | $159.01B | $626.09B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $267.24 |
52-Week Low | $57.93 | $172.78 |
Enterprise Value | $223.42B | $654.37B |
Dividend Yield | 1.67% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.20, down 4.69% today, with technical indicators showing bearish momentum. The stock shows solid fundamentals with 2025 revenue of $59.32B and net income margin improving to 11.52%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 estimate. Analyst consensus remains bullish with 57.8% buy ratings and $90.17 price target, representing 14% upside potential from current levels.
The outlook remains positive given strong cash flow generation and debt reduction trends, though near-term technical weakness and competitive pressures in the beer industry present risks. Institutional activity shows mixed signals with recent share sales by Cetera Investment Advisers offset by Bank of New York Mellon purchases.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
